Popular Articles
Stretch Mark

Diabetes Specialists Call For Drug Regulators To Step In To Clarify Lantus Concerns, UK
BRITAIN"S top diabetes specialists added their weight to calls for European drug regulatory bodies to launch an urgent investigation into the popular insulin treatment glargine (Lantus). The move by the Association of British Clinical Diabetologists (ABCD) follows this week"s publication of four studies, which raise possible concern about an increased risk of the development of cancer in people who use this long-acting insulin therapy.
generic viagra online
House Committee Approves Reform Bill; Full House Debate Scheduled For After August Recess
The House Energy and Commerce Committee on July 31 approved its health care reform bill (HR 3200) by a 31-28 vote that was mostly along party lines, the AP/Seattle Times reports. Among the many amendments considered during the markup, the committee rejected an amendment offered by Reps. Joe Pitts (R-Pa) and Bart Stupak (D-MI) to prohibit government subsidies to any insurance plans that offers abortion coverage, effectively prohibiting abortion coverage for customers eligible for public premium assistance. The amendment was rejected by a 27-31 vote. Another provision approved on July 30 would neither require nor prohibit insurance companies from providing coverage for abortion services.The approved bill includes provisions limiting how much insurers can increase premiums and gives the federal government the power to negotiate with drug companies for lower prices under Medicaid. The provisions were part of an effort by Democrats on the committee to reconcile the demands of liberals and conservatives, the AP/Times reports. The bill also would require insurance companies to sell coverage to anyone seeking it, regardless of pre-existing conditions. The government would provide subsidies to lower-income families to help them afford policies. In addition, the legislation would establish health insurance exchanges offering a variety of insurance plans, where consumers with or without subsidies could purchase health insurance (Espo/Werner, AP/Seattle Times, 8/1).Five of the committee"s Democrats joined all 23 Republicans in opposing the measure, the Washington Post"s "Capitol Briefing" reports. The five Democrats who voted against the bill were Reps. John Barrow (Ga.), Rick Boucher (Va.), Jim Matheson (Utah), Charlie Melancon (La.) and Bart Stupak (Mich.) (Kane, "Capitol Briefing," Washington Post, 7/31).The committee was the last of three House panels to take action on the legislation, although the vote comes several weeks after the White House and Democratic leaders originally wanted, the AP/Times reports. The full House is expected to vote on the bill after policymakers return from their August recess.Although the House"s agenda has moved slower than party leaders had hoped, it still was faster than the action in the Senate, according to the AP/Times (AP/Seattle Times, 8/1). Senate Finance Committee Chair Max Baucus (D-Mont.) on July 30 announced that the panel will not mark up a health care reform bill this week after Republican negotiators urged that the speed of discussion in the Senate be slowed, the Post"s "44" reports. The announcement means that health care reform legislation will not be out of committee in both chambers before the summer recess (Pershing, "44," Washington Post, 7/31).Catholic Bishops Say That House Bill Could Expand Abortion Coverage In related news, the U.S. Conference of Catholic Bishops in a letter to members of the House Energy and Commerce Committee voiced its opposition to the reform bill, arguing that it could be used to require private health insurance plans to cover abortion services, the Post reports. The bill has been opposed by conservative Christian groups for weeks, with the groups arguing that it could be used to expand abortion rights, the Post reports.In the letter, Cardinal Justin Rigali -- chair of the Committee on Pro-Life Activities -- said the bill could increase federal funding for abortion services because some government funding would not be covered by the Hyde Amendment, which currently bans the use of federal Medicaid funds for abortion services. Rigali also said the bill could overturn state laws that restrict access to abortion services, such as parental notification laws. In addition, Rigali said the bill should continue to ensure provider conscience rights to protect Catholic health care workers who refuse to provide abortion services based on their religious or moral beliefs (Washington Post, 8/1).
News of the day
What Is Lyme Disease? What Are Symptoms Of Lyme Disease?
Lyme disease was coined Lyme because it was first reported in three Connecticut towns, including Lyme and Old Lyme, in 1975. It was originally thought to be juvenile rheumatoid arthritis in these three towns. A study carried out by scientists from the Yale School of Public Health, USA and the University of Bath, England, revealed that "Lyme Disease In The U.S. Originated In Europe".
Public Health

Can-Fite-Completed Patient Enrollment For The Phase II Trial In Psoriasis With CF101

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has achieved yet another goal by completion of patients" enrollment in its phase II Psoriasis trial. Approximately 70 patients were enrolled to this study, randomized into 4 groups treated with 1, 2 and 4 mg of CF101 and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 10 sites in Israel and Europe. The company estimates to release study data on Q3 2009. A point to note it that similarly to the patients in the Dry Eye study, which was recently successfully concluded, the patients in the current study were also treated with CF101 as a stand alone. Psoriasis is a skin condition that affects 2% to 3% of the general population. The disease is manifested by scaly plaques on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. General anti-inflammatory agents such as topical corticosteroids, Methotrexate or phototherapy are only partially effective and are limited by safety issues. Recently, novel biologics targeting the underlying immuno-pathogenesis of the disease have been introduced, such as Enbrel, which blocks the activity of the inflammatory cytokine tumor necrosis factor-í± (TNF-í±). Still, a significant need remains for novel drugs for patients who do not respond to existing therapies or for whom these therapies are unsuitable. The market share for Psoriasis is estimated at US$ 3.5 billion annually. The oral administration of Can-Fite"s CF101, the drug"s mechanism of action (suppression of the inflammatory mediator TNF-í±) and its excellent safety profile (tested on more than 600 subjects in other trials), support its use for the treatment of psoriasis. Prof. Pnina Fishman, CEO of Can-Fite, said today that, "We are very happy with the progress in our clinical development program and looking forward to analyze the data of this study in which CF101 was given as a monotherapy. It is our first trial in the dermatology field and the immuno-modulatory activities of CF101 render it a possible attractive drug candidate for these clinical conditions." Can-Fite Biopharma LTD


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):